Candriam S.C.A. Myovant Sciences Ltd. Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 22, 2021	SELL	$13.8 - $27.62 $6.72 Million - $13.4 Million	-486,864 Closed	0 $0
Q3 2020 Oct 19, 2020	BUY	$14.05 - $22.6 $3.73 Million - $6 Million	265,461 Added 119.9%	486,864 $6.84 Million
Q2 2020 Jul 23, 2020	BUY	$7.34 - $20.84 $717,426 - $2.04 Million	97,742 Added 79.04%	221,403 $4.57 Million
Q1 2020 May 26, 2020	BUY	$6.55 - $14.76 $189 - $428	29 Added 0.02%	123,661 $1.88 Million
Q4 2019 Jan 21, 2020	BUY	$4.2 - $19.21 $519,254 - $2.37 Million	123,632 New	123,632 $2,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.